I

ICU Medical

IV therapy systems and safety solutions

Overview

ICU Medical focuses exclusively on IV therapy across the care continuum. It develops and supplies IV therapy systems, software, and consumables designed to fit existing clinical workflows and improve patient safety and experience. Its product line includes dedicated and non-dedicated IV sets and needle-free connectors that reduce bacterial transfer, a broad range of IV smart pumps for large-volume, pain-management, and ambulatory use, and IV medication safety software that interoperates with IV-EHR systems to support safer, more efficient care. The company differentiates itself by being 100% focused on IV therapy (a result of acquiring Hospira Infusion Systems) with extensive manufacturing and supply capabilities and the broadest IV pump portfolio, enabling strong compatibility with many EHR systems. ICU Medical’s goal is to improve the safety and efficiency of IV therapy and strengthen the clinical experience for patients and caregivers.

Work here?Claim your company

About ICU Medical

Simplify's Rating
Why ICU Medical is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Enterprise SoftwareHealthcare

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Clemente, CA

Founded

1984

Get referred to ICU Medical

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Q3 2026 revenue rose 4.4% to $556.4 million, with 42% gross margin.
  • Management reaffirmed 2026 guidance on November 5, targeting the high end of ranges.
  • New clearances and 2027 launches for MicroClave, DEHP-free bags, and disinfection caps expand share.

What critics are saying

  • Q3 2026 Vital Care fell 10% organically from logistics disruptions and integration problems.
  • Management said Medfusion 5000 still awaits FDA clearance after additional testing requests.
  • P/E near 146 and insider sales in August-September 2026 leave little error room.

What makes ICU Medical unique

  • ICU Medical owns infusion systems, consumables, and critical-care products across hospital workflows.
  • Its installed base plus 2027-2029 pump replacements creates sticky recurring revenue.
  • Global manufacturing and Otsuka JV deepen supply control across IV solutions and distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Stock Price

Company News

GlobeNewswire
Nov 6th, 2026
ICU Medical to present at the 2026 Jefferies Global Healthcare Conference in London.

ICU Medical to present at the 2026 Jefferies Global Healthcare Conference in London. SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 2026 Jefferies Global Healthcare Conference being held in London, November 15-18, 2026. ICU Medical's presentation will be on Wednesday, November 18, 2026, at 5:00 p.m. BST (12:00 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, November 18, 2026. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay. About ICU Medical ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com ICR, Inc. John Mills, Managing Partner (646) 277-1254

MarketBeat
Nov 6th, 2026
ICU Medical (NASDAQ:ICUI) posts earnings results, beats estimates by $0.30 EPS.

ICU Medical (NASDAQ:ICUI) posts earnings results, beats estimates by $0.30 EPS. November 6, 2026 Key points. * ICU Medical beat Q3 estimates: Adjusted EPS was $2.44, $0.30 above consensus, while revenue of $556.22 million topped forecasts and rose 4.4% year over year. * Growth and outlook were solid: Organic revenue rose 5%, adjusted EBITDA increased 8%, and management expects full-year adjusted EPS and EBITDA to finish near the high end of its guidance ranges. * Operational challenges remain: Integration-related logistics issues disrupted international deliveries and contributed to a 10% organic decline in Vital Care; management expects most problems to be resolved in Q4. * MarketBeat previews the top five stocks to own by December 1st. ICU Medical (NASDAQ:ICUI - Get Free Report) announced its earnings results on Thursday. The medical instruments supplier reported $2.44 earnings per share for the quarter, topping analysts' consensus estimates of $2.14 by $0.30, FiscalAI reports. The company had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.03 earnings per share. Here are the key takeaways from ICU Medical's conference call: * Q3 revenue was $556 million, up 5% organically, while adjusted EBITDA rose 8% to $114 million and adjusted EPS increased 20% to $2.44. Consumables and Infusion Systems each posted record sales. * Management expects full-year adjusted EBITDA of $415 million-$435 million and adjusted EPS of $8.60-$9.00 to finish toward the high end of its existing ranges. Adjusted gross margin reached 42%, and the company reiterated its goal of reaching 43% by the end of 2027. * Free cash flow was $83 million in Q3, supporting about $80 million of debt repayment and bringing net leverage to 2.0x. However, year-to-date cash flow benefited from tariff refunds and lower capital spending, and management expects Q4 free cash flow to be lower than Q3. * Integration-related logistics problems disrupted international deliveries and weighed on Vital Care, which declined 10% organically in Q3; management expects a larger full-year decline for the segment. It said most of the operational issues should be resolved in Q4. * ICU Medical reported progress on its product pipeline, including approvals for infusion pumps in Canada and Europe and plans to file a revised Medfusion 5000 syringe-pump application in the coming weeks. Several Consumables launches are planned for 2027, though the company said pump-install-base replacement is likely to unfold over 2027-2029. ICU Medical price performance. NASDAQ ICUI traded up $4.46 during midday trading on Friday, hitting $172.11. The company had a trading volume of 464,850 shares, compared to its average volume of 283,141. The firm has a 50-day moving average price of $162.97 and a 200-day moving average price of $149.18. The company has a market capitalization of $4.30 billion, a PE ratio of 145.86, a P/E/G ratio of 2.17 and a beta of 0.88. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical has a twelve month low of $113.37 and a twelve month high of $192.85. Insider activity at ICU Medical. In related news, COO Christian Voigtlander sold 8,929 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the transaction, the chief operating officer owned 37,377 shares of the company's stock, valued at $6,837,374.61. The trade was a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Virginia Sanzone sold 4,856 shares of the company's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total transaction of $819,158.64. Following the sale, the vice president directly owned 14,604 shares of the company's stock, valued at $2,463,548.76. This represents a 24.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,830 shares of company stock worth $3,905,003 in the last quarter. 2.10% of the stock is currently owned by corporate insiders. Key stories impacting ICU Medical. Here are the key news stories impacting ICU Medical this week: * Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. * Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. * Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. * Management will present at the Jefferies Global Healthcare Conference in London on November 15-18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Wall Street analyst weigh in. Several research analysts have weighed in on ICUI shares. Weiss Ratings upgraded ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Piper Sandler upped their price target on shares of ICU Medical from $195.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday. Zacks Research lowered shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Raymond James Financial reiterated a "strong-buy" rating and issued a $200.00 price objective on shares of ICU Medical in a research note on Friday, August 7th. Finally, Needham & Company LLC boosted their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $195.20. About ICU Medical. ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings. The company's portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs. Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira's infusion systems business in 2017 and Smiths Medical in 2022. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider ICU Medical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list. While ICU Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power. Continue following MarketBeat

Associated Press
Nov 5th, 2026
ICU Medical Q3 revenue rises to $560.4M, swings to $26.8M profit; guidance seen at high end

ICU Medical reported third quarter 2026 revenue of $560.4 million, up from $537.0 million a year earlier. The San Clemente, California, medical products maker said results for its Infusion Systems line beat expectations. Net income was $26.8 million, or $1.07 per diluted share, against a net loss of $3.4 million a year earlier. Gross margin rose to 42% from 37%. Adjusted EBITDA was $113.9 million, compared with $105.9 million, and adjusted diluted earnings per share were $2.44, up from $2.03. The company reaffirmed its 2026 guidance but expects to finish near the high end. It forecasts net income of $73 million to $83 million and adjusted EBITDA of $415 million to $435 million.

Yahoo Finance
Sep 17th, 2026
ICU Medical CFO sells $1.6M in shares, stock up 35% amid strong performance

ICU Medical CFO Brian Bonnell sold 9,307 shares of the company on 31 August 2026, according to an SEC Form 4 filing. The transaction was valued at $1.6 million. The sale was executed through multiple transactions at prices ranging from $170.57 to $174.08 per share under a Rule 10b5-1 trading plan. This mechanism allows insiders to establish predetermined selling schedules to avoid concerns about trading on non-public information. Following the transaction, Bonnell holds 62,443 direct shares in the medical technology firm, valued at $10.8 million. The stock had experienced a 35% return in the period leading up to the filing date. ICU Medical develops and manufactures medical devices for infusion therapy and critical care applications. The company has approximately 13,000 employees and generates $2.2 billion in revenue.

Yahoo Finance
Aug 10th, 2026
ICU Medical shares jump 10% on strong Q2 earnings beat and raised guidance

ICU Medical shares jumped 10.2% after the medical device company reported strong second-quarter results that exceeded Wall Street expectations. The company posted adjusted earnings of $2.37 per share, beating the average analyst estimate of $1.91. Revenue reached $551.7 million, up 1.5% year-on-year and also surpassing forecasts. Free cash flow showed significant improvement at $61.64 million, recovering from negative $8.49 million in the same quarter last year. Following the strong performance, ICU Medical raised its full-year adjusted earnings guidance to $8.80 per share at the midpoint, above previous analyst estimates. The company's shares have risen 31.5% since the beginning of the year, reaching a new 52-week high of $182.16.

Recently Posted Jobs

Sign up to get curated job recommendations

ICU Medical is Hiring for 87 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs